A trial opened to investigate CFI-400945, by Treadwell Therapeutics, as a potential oral therapy for people with metastatic castration-resistant prostate cancer (mCRPC), the company announced in a press release. It is one of several sub-studies within a larger Phase 2 clinical trial (NCT03385655) that is evaluating various treatment candidates, including targeted therapies, immunotherapies, and chemotherapies, as possible precision treatments for mCRPC patients. People enrolled first undergo a liquid biopsy to identify specific mutations evident in cancer cell DNA…
You must be logged in to read/download the full post.
The post New Targeted Therapy Trial Opens, Part of PC-BETS Metastatic CRPC Study appeared first on BioNewsFeeds.